519 related articles for article (PubMed ID: 34312954)
1. Effectiveness of direct acting antiviral agents for hepatitis C virus related recurrent hepatocellular carcinoma patients who had multiple courses of recurrence.
Ohki T; Sato K; Kondo M; Goto E; Sato T; Kondo Y; Akamatsu M; Sato S; Yoshida H; Koike Y; Obi S
J Viral Hepat; 2021 Nov; 28(11):1597-1603. PubMed ID: 34312954
[TBL] [Abstract][Full Text] [Related]
2. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Direct-Acting Antiviral Therapy on the Risk of Recurrence after Curative Resection in Patients with Hepatitis-C-Virus-Related Early Stage Hepatocellular Carcinoma.
Chen YS; Huang KH; Wang PM; Chuang CH; Yong CC; Liu YW; Huang PY; Yao CC; Lin YP; Tsai MC
Medicina (Kaunas); 2022 Feb; 58(2):. PubMed ID: 35208582
[No Abstract] [Full Text] [Related]
4. Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicentre study by the Japanese Red Cross Liver Study Group.
Mashiba T; Joko K; Kurosaki M; Ochi H; Marusawa H; Uchida Y; Fujii H; Kojima Y; Yoshida H; Goto T; Akahane T; Kondo M; Tsuji K; Mitsuda A; Hasebe C; Kusakabe A; Sohda T; Furuta K; Kobashi H; Ogawa C; Ide Y; Arai H; Okada K; Shigeno M; Nonogi R; Izumi N
J Viral Hepat; 2022 Jul; 29(7):551-558. PubMed ID: 35548866
[TBL] [Abstract][Full Text] [Related]
5. Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy.
Nishibatake Kinoshita M; Minami T; Tateishi R; Wake T; Nakagomi R; Fujiwara N; Sato M; Uchino K; Enooku K; Nakagawa H; Asaoka Y; Shiina S; Koike K
J Hepatol; 2019 Jan; 70(1):78-86. PubMed ID: 30336183
[TBL] [Abstract][Full Text] [Related]
6. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
[TBL] [Abstract][Full Text] [Related]
7. The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment.
Kuo YH; Wang JH; Chang KC; Hung CH; Lu SN; Hu TH; Yen YH; Kee KM; Chen CH
Invest New Drugs; 2020 Feb; 38(1):202-210. PubMed ID: 31701431
[TBL] [Abstract][Full Text] [Related]
8. Serum α-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment.
Kuwano A; Yada M; Nagasawa S; Tanaka K; Morita Y; Masumoto A; Motomura K
J Viral Hepat; 2022 Jan; 29(1):35-42. PubMed ID: 34661320
[TBL] [Abstract][Full Text] [Related]
9. Predictors of hepatocellular carcinoma recurrence associated with the use of direct-acting antiviral agent therapy for hepatitis C virus after curative treatment: A prospective multicenter cohort study.
Nakano M; Koga H; Ide T; Kuromatsu R; Hashimoto S; Yatsuhashi H; Seike M; Higuchi N; Nakamuta M; Shakado S; Sakisaka S; Miuma S; Nakao K; Yoshimaru Y; Sasaki Y; Oeda S; Eguchi Y; Honma Y; Harada M; Nagata K; Mawatari S; Ido A; Maeshiro T; Matsumoto S; Takami Y; Sohda T; Torimura T
Cancer Med; 2019 May; 8(5):2646-2653. PubMed ID: 30900818
[TBL] [Abstract][Full Text] [Related]
10. Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C.
Kawagishi N; Suda G; Yamamoto Y; Baba M; Furuya K; Maehara O; Ohnishi S; Yoshida S; Fu Q; Yang Z; Hosoda S; Tokuchi Y; Kitagataya T; Ohara M; Suzuki K; Nakai M; Sho T; Natsuizaka M; Ogawa K; Sakamoto N
Viruses; 2023 Jan; 15(1):. PubMed ID: 36680221
[TBL] [Abstract][Full Text] [Related]
11. Risk of Hepatocellular Cancer Recurrence in Hepatitis C Virus+ Patients Treated with Direct-Acting Antiviral Agents.
Zou WY; Choi K; Kramer JR; Yu X; Cao Y; El-Serag HB; Kanwal F
Dig Dis Sci; 2019 Nov; 64(11):3328-3336. PubMed ID: 31041639
[TBL] [Abstract][Full Text] [Related]
12. Direct-Acting Antivirals and Hepatocellular Carcinoma: No Evidence of Higher Wait-List Progression or Posttransplant Recurrence.
Piñero F; Boin I; Chagas A; Quiñonez E; Marciano S; Vilatobá M; Santos L; Anders M; Hoyos Duque S; Soares Lima A; Menendez J; Padilla M; Poniachik J; Zapata R; Maraschio M; Chong Menéndez R; Muñoz L; Arufe D; Figueroa R; Mendizabal M; Hurtado Gomez S; Stucchi R; Maccali C; Vergara Sandoval R; Bermudez C; McCormack L; Varón A; Gadano A; Mattera J; Rubinstein F; Carrilho F; Silva M
Liver Transpl; 2020 May; 26(5):640-650. PubMed ID: 32133773
[TBL] [Abstract][Full Text] [Related]
13. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy.
Nagaoki Y; Imamura M; Nishida Y; Daijo K; Teraoka Y; Honda F; Nakamura Y; Morio K; Fujino H; Nakahara T; Kawaoka T; Tsuge M; Hiramatsu A; Kawakami Y; Miki D; Hiyama Y; Ochi H; Chayama K; Aikata H
J Med Virol; 2019 Apr; 91(4):650-658. PubMed ID: 30381831
[TBL] [Abstract][Full Text] [Related]
14. HCV Eradication in Primary or Secondary Prevention Optimizes Hepatocellular Carcinoma Curative Management.
Nahon P; Layese R; Cagnot C; Asselah T; Guyader D; Pol S; Pageaux GP; De Lédinghen V; Ouzan D; Zoulim F; Audureau E;
Cancer Prev Res (Phila); 2021 May; 14(5):581-592. PubMed ID: 33608313
[TBL] [Abstract][Full Text] [Related]
15. Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria.
Ochi H; Hiraoka A; Hirooka M; Koizumi Y; Amano M; Azemoto N; Watanabe T; Yoshida O; Tokumoto Y; Mashiba T; Yokota T; Abe M; Michitaka K; Hiasa Y; Joko K
J Gastroenterol; 2021 Jan; 56(1):90-100. PubMed ID: 33278003
[TBL] [Abstract][Full Text] [Related]
16. Analyzing risk factors and developing a stratification system for hepatocellular carcinoma recurrence after interferon-free direct-acting antiviral therapy in chronic hepatitis C patients.
Luan CH; Su PS; Chu CJ; Lin CC; Su CW; Luo JC; Lee IC; Chi CT; Lee SD; Wang YJ; Lee FY; Huang YH; Hou MC
J Chin Med Assoc; 2024 Apr; 87(4):357-368. PubMed ID: 38180018
[TBL] [Abstract][Full Text] [Related]
17. Treatment rates and factors associated with direct-acting antiviral therapy for insured patients with hepatitis C-related hepatocellular carcinoma - A real-world nationwide study.
Kam LY; Yeo YH; Ji F; Henry L; Cheung R; Nguyen MH
Aliment Pharmacol Ther; 2024 Feb; 59(3):350-360. PubMed ID: 37937485
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
[TBL] [Abstract][Full Text] [Related]
19. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study.
Cabibbo G; Petta S; Calvaruso V; Cacciola I; Cannavò MR; Madonia S; Distefano M; Larocca L; Prestileo T; Tinè F; Bertino G; Giannitrapani L; Benanti F; Licata A; Scalisi I; Mazzola G; Cartabellotta F; Alessi N; Barbàra M; Russello M; Scifo G; Squadrito G; Raimondo G; Craxì A; Di Marco V; Cammà C;
Aliment Pharmacol Ther; 2017 Oct; 46(7):688-695. PubMed ID: 28791711
[TBL] [Abstract][Full Text] [Related]
20. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study.
Singal AG; Rich NE; Mehta N; Branch A; Pillai A; Hoteit M; Volk M; Odewole M; Scaglione S; Guy J; Said A; Feld JJ; John BV; Frenette C; Mantry P; Rangnekar AS; Oloruntoba O; Leise M; Jou JH; Bhamidimarri KR; Kulik L; Tran T; Samant H; Dhanasekaran R; Duarte-Rojo A; Salgia R; Eswaran S; Jalal P; Flores A; Satapathy SK; Wong R; Huang A; Misra S; Schwartz M; Mitrani R; Nakka S; Noureddine W; Ho C; Konjeti VR; Dao A; Nelson K; Delarosa K; Rahim U; Mavuram M; Xie JJ; Murphy CC; Parikh ND
Gastroenterology; 2019 May; 156(6):1683-1692.e1. PubMed ID: 30660729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]